Sanchine三精品牌怎么样 申请店铺

我要投票 Sanchine三精在补钙行业中的票数:335 更新时间:2025-04-27
Sanchine三精是哪个国家的品牌?「Sanchine三精」是 哈药集团三精制药有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人芦传有在2015期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力Sanchine三精品牌出海!通过在本页面挂载Sanchine三精品牌的产品链接和联系方式,可以提高Sanchine三精产品曝光!跨境电商爆单神器,目前只要100元/年哦~

Sanchine三精怎么样

三精制药始建于1950年,初期以生产肌肉和静脉水针剂为主,是黑龙江省最早的专业化生产水针剂和国内最早引进国外水针剂一连机生产设备的企业,是最早通过国家GMP认证的医药企业之一。公司现总占地面积110万平方米,员工总数近6000人,是以OTC产品、处方药与保健食品为主、医药原料和制剂并重的综合性制药企业。2004年,“三精”品牌被国家工商总局认定为“驰名保护”。2011年5月13日,“三精”品牌在“2011中国最有价值品牌评价”中,经权威机构认定,品牌价值为68.93亿元人民币。

目前,三精制药拥有下属子公司15家,其中工业子公司8家、商业子公司5家、其他相关产业子公司2家。截至目前,公司口服液、口服溶液剂、小容量注射剂(非最终灭菌)、冻干粉针剂、片剂、粉针剂、胶囊剂、颗粒剂、合剂、糖浆剂、洗剂、茶剂、散剂13个剂型及无菌原料药(磷霉素钠、炎琥宁)、原料药(拉西地平、盐酸罗沙替丁醋酸酯)均通过2010版GMP认证。其中,口服液剂型产品年生产能力达16亿支。公司主导产品包括葡萄糖酸钙口服溶液、葡萄糖酸锌口服液、双黄连口服液、司乐平片等。近年来,通过药品、保健品的新产品立项研发,不断完善产品线,丰富产品阵容。

六十余年的制药经验,先进的技术设备,一流的管理手段,完善的科研开发体系,使“三精”牌在国内外丰享盛誉。三精一直将产品和服务视为核心竞争力,同时高度重视产品的研发,2004年建成较具规模的研发中心,已成为黑龙江省药物制剂工程技术研究中心、黑龙江省西药制剂重点实验室,承担“十一五”“重大新药创制”科技重大专项——“新型口服缓控释制剂及工艺技术平台”课题和“十二五”“重大新药创制”科技重大专项——“抗阿尔茨海默病药重酒石酸卡巴拉汀及其胶囊的研究开发”课题。2008年,公司成为“国家首批创新型企业”,2012年入选国家火炬计划重点高新技术企业。公司还先后荣获了全国质量管理先进企业、全国守合同重信用企业、全国医药系统优秀企业、全国“五·一劳动奖状”先进集体、“全国企业文化优秀成果奖”、“全国医药行业药品质量诚信建设示范企业”、“21315国际质量信用AAA++级”、“中国优秀诚信企业”、“中国化学制药行业工业企业综合实力百强”企业、黑龙江省“科技创新优秀企业奖”等荣誉称号。

Sanjing pharmaceutical was founded in 1950. At the early stage, it mainly produces muscle and intravenous water injection. It is the first professional enterprise in Heilongjiang Province to produce water injection and the first enterprise in China to introduce foreign water injection production equipment. It is also one of the first pharmaceutical enterprises to pass the national GMP certification. The company now covers an area of 1.1 million square meters and employs nearly 6000 people. It is a comprehensive pharmaceutical enterprise focusing on OTC products, prescription drugs and health food, with equal emphasis on pharmaceutical raw materials and preparations. In 2004, "three fine" brand was recognized as "well-known protection" by the State Administration for Industry and commerce. On May 13, 2011, in the "2011 China's most valuable brand evaluation", the brand value of "three fine" was recognized by the authority as RMB 6.893 billion. At present, Sanjing pharmaceutical has 15 subsidiaries, including 8 Industrial subsidiaries, 5 Commercial subsidiaries and 2 other related industrial subsidiaries. Up to now, 13 dosage forms of the company's oral liquid, oral solution, small volume injection (non final sterilization), freeze-dried powder injection, tablet, powder injection, capsule, granule, mixture, syrup, lotion, tea, powder, sterile API (fosfomycin sodium, Yanhuning), API (lacidipine, rosattidine hydrochloride acetate) have passed GMP certification of 2010 version. Among them, the annual production capacity of oral liquid dosage products reached 1.6 billion. The company's leading products include calcium gluconate oral solution, zinc gluconate oral solution, Shuanghuanglian oral solution, and silepin tablets. In recent years, through the research and development of new products of drugs and health products, the product line has been continuously improved and the product lineup has been enriched. With more than 60 years of pharmaceutical experience, advanced technology and equipment, first-class management means, and perfect scientific research and development system, the "three refined" brand enjoys a good reputation at home and abroad. Sanjing has always regarded products and services as its core competitiveness, and attached great importance to product research and development. In 2004, it established a relatively large-scale research and development center, which has become Heilongjiang pharmaceutical engineering and technology research center and Heilongjiang western pharmaceutical Key Laboratory, undertaking the major science and technology project of "11th Five Year plan" and "major new drug creation" -- new oral sustained and controlled release preparations and technology "Platform" project and "12th Five Year Plan" science and technology major project of "major new drug creation" - research and development of anti Alzheimer's disease drug kabalatin tartrate and its capsule ". In 2008, the company became "the first batch of national innovative enterprises", and in 2012, it was selected as a key high-tech enterprise in the national torch plan. The company has also won the national advanced quality management enterprise, the national contract abiding and trustworthy enterprise, the national excellent pharmaceutical system enterprise, the national advanced collective of "May 1st Labor Award", "national enterprise culture excellent achievement award", "national pharmaceutical industry pharmaceutical quality and integrity construction demonstration enterprise", "21315 International quality and credit AAA + + level", "China excellent and integrity enterprise" "Top 100 enterprises with comprehensive strength in China's chemical and pharmaceutical industry" and "science and technology innovation excellent enterprise award" of Heilongjiang Province, etc.

本文链接: https://brand.waitui.com/41c6b1011.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

格力电器:2024年归母净利润同比增长10.91%,拟10派20元

36氪获悉,格力电器4月27日公告,2024年营业收入1891.64亿元,同比下降7.26%;归母净利润321.85亿元,同比增长10.91%,基本每股收益5.83元。公司拟每10股派发现金红利20元(含税)。同日披露的2025年一季报显示,公司一季度实现营业收入415.07亿元,同比增长14.14%;归母净利润59.04亿元,同比增长26.29%。

19分钟前

泸州老窖:2024年净利润同比增长1.71%,拟10派45.92元

36氪获悉,泸州老窖公告,公司2024年实现营业收入311.96亿元,同比增长3.19%,净利润134.73亿元,同比增长1.71%;基本每股收益9.18元。公司拟每10股派发现金红利45.92元(含税)。泸州老窖同日披露2025年一季报,一季度实现净利润45.93亿元,同比增长0.41%。

19分钟前

商务部副部长盛秋平:将打造一批国际消费集聚区和入境消费友好商圈

商务部副部长盛秋平4月27日在国新办发布会上表示,商务部将继续深化国际消费中心城市建设,支持推动扩大入境消费。商务部将打造国际化消费环境,指导各地优化涉外支付服务,提升离境退税政策效能,打造一批国际消费集聚区和入境消费友好商圈,打通外国人在华消费堵点、痛点。近期财政部门正积极研究对有关方面给予专项资金支持。(证券时报)

19分钟前

中金公司:美图生活场景国内付费渗透率达5.2%

36氪获悉,中金公司研报透露,预计截至2月,美图公司生活场景下的国内付费渗透率已经达到5.2%。该场景下的产品包括美图秀秀、美颜相机、Wink等。据研报显示,美图生活场景产品国内付费渗透率突破5%,主要得益于生成式AI对传统功能的重新构建,如用AI去双下巴取代传统的手动推图,带来更好的用户体验和效果,促进订阅转化率提升。美图对生活场景应用订阅渗透率的长期目标为10%。

19分钟前

惠誉博华:商业银行扩表节奏趋缓

36氪获悉,近日惠誉博华商业银行2024年度业绩点评。报告显示,2024年商业银行总资产同比增速回落至4.8%,结束此前连续三年的双位数扩张周期。从银行机构类型看呈现显著分化态势:城商行以8.9%的资产增速领跑,农商行以6.0%的增速紧随其后,国有大行与股份制银行分别录得3.9%和2.7%的增速。这种梯度差异映射出不同类别银行面临的经营环境——头部城商行凭借区域经济韧性维持相对活跃的资产扩张,而股份制银行负债端受制于存款成本刚性约束难以匹配国有大行资金优势,资产端受风险偏好与定价能力限制难以深度渗透区域下沉市场,导致信贷资源配置效率持续承压,近三年资产增速中枢较2019至2021年下降逾6个百分点,信贷市场正从增量竞争向存量优化转换。

19分钟前

本页详细列出关于Sanchine三精的品牌信息,含品牌所属公司介绍,Sanchine三精所处行业的品牌地位及优势。
咨询